Beta Blockers and Melanoma

Aleksandra Vojvodic; Petar Vojvodic; Tatjana Vlaskovic-Jovicevic; Goran Sijan; Sanja Dimitrijevic; Zorica Peric-Hajzler; Dusica Matovic; Wollina Uwe; Michael Tirant; Van Thuong Nguyen; Massimo Fioranelli; Torello Lotti

doi:10.3889/oamjms.2019.782

Authors

Aleksandra Vojvodic Department of Dermatology and Venereology, Military Medical Academy, Belgrade, Serbia
Petar Vojvodic Clinic for Psychiatric Disorders â€œDr. Laza Lazarevicâ€, Belgrade, Serbia
Tatjana Vlaskovic-Jovicevic Clinic for Psychiatric Disorders â€œDr. Laza Lazarevicâ€, Belgrade, Serbia
Goran Sijan Clinic for Plastic Surgery and Burns, Military Medical Academy, Belgrade, Serbia
Sanja Dimitrijevic Department of Gynecology, Military Medical Academy, Belgrade, Serbia
Zorica Peric-Hajzler Military Medical Academy, Belgrade, Serbia
Dusica Matovic Military Medical Academy, Belgrade, Serbia
Wollina Uwe Department of Dermatology and Allergology, StÃ¤dtisches Klinikum Dresden, Dresden, Germany
Michael Tirant University Guglielmo Marconi, Rome, Italy
Van Thuong Nguyen National Hospital of Dermatology and Venereology, Hanoi, Vietnam
Massimo Fioranelli Department of Nuclear Physics, sub-nuclear and radiation, G. Marconi University, Rome, Italy
Torello Lotti University of Rome G. Marconi, Rome, Italia

DOI:

https://doi.org/10.3889/oamjms.2019.782

Keywords:

beta blockers, melanoma

Abstract

Understanding the mechanisms of cancer immune-tolerance is one of the most important challenges. Several studies have demonstrated the potential anticarcinogenic effects of beta-blockers, in patients with prostate cancer, breast cancer, and melanoma. At the other side variety of dermatoses may be caused or aggravated by Î²-blockers-psoriasis, lichen planus-like drug eruptions (LDE), acrocyanosis, alopecia etc. Beta-blockers have been shown to improve the prognosis of melanoma patients significantly. Propranolol inhibits melanoma by downregulating the tumour angiogenesis but also tumour cell proliferation, invasiveness and local immune suppression. Studies showed that only Î²3-but, not Î²2-adrenoceptors, were up-regulated under hypoxia in peripheral blood mononuclear cells and selectively expressed in immune cell sub-populations including Treg, MDSC, and NK. They increased NK and CD8 number and cytotoxicity. Catecholamines may retard melanoma progression and that Î²-blockers may have unrecognised potential as a therapeutic intervention for melanoma, in the prevention of the growth of melanoma in all stages and as adjuvant therapy with other targeted and immune therapies for melanoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Author Biography

Torello Lotti, University of Rome G. Marconi, Rome, Italia

Prof. Lotti is Full Professor of the Dermatology and Venereology at University of Studies Guglielmo Marconi, Rome, Italy. He is Honorary Professor of Dermatology - China Medical University Shenyang (2011), Lecturer at the New York Academy of Sciences "Howard Fox Memorial Lecture" (14 March 2012 - New York, NY â€“ USA), and Chair, Executive Scientific Committee Vitiligo Research Foundation, New York , NY , USA. He is President of the World Health Academy, Dermatology since 2013. He has been Full Professor of the Dermatology and Venereology Division at University of Florence School of Medicine, Florence, Italy, from 2006 to 2010. He is Visiting Professor in six International Universities worldwide, and Key Note Lecturer in several international dermatology Societies. His activities in serving Dermatology have been numerous: President of the Italian Society of Dermatology and Venereology (SIDeMaST , 2009-2010) and President of the International Society of Dermatology ( ISD, 2009-2010), President of the European Society for Cosmetic and Aesthetic Dermatology (2003-2004), Editor in Chief of the Journal of the European Academy of Dermatology and Venereology (1992-2002) , Editor "Therapeutic Hotline"- Dermatologic Therapy (2007-)and served as Editor in Chief of the Giornale Italiano di Dermatologia in the period of presidency of the Societa' Italiana di Dermatologia (2009-2010). He has been President of numerous international congresses and is currently Editor in Chief of the Giornale Italiano di Dermatologia e Venereologia ( 2010-2020 ). He is Ordinary Member of the main Scientific Societies worldwide (EADV, SIDEV , ESDR , ISD, AAD, SID) and Honorary Member of several Scientific Societies of the Dermatology field. Moreover, he is a Scientific reviewer of ten sectorial journals, among which are the British Journal of Dermatology, Journal of Investigative Dermatology, Journal of the American Academy of Dermatology , Dermatologic Therapy. He has authored 1054 scientific publications (393 peer reviewed articles, 288 books chapters e 365 abstracts). For more information, see www.torellolotti.it